Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Washington State Nurses Association (WSNA), representing more than 1,600 registered nurses at Sacred Heart Medical Center, is holding a press conference today to highlight serious concerns about the safety of nurses and patients at Sacred Heart Medical Center during this H1N1 pandemic.
A commentary in the December issue of The Lancet Infectious Diseases brings to light the gaps in knowledge on the transmission of a common pathogen - the influenza virus - and its impact on decisions about how best to protect health care workers. Infectious diseases specialist Leonard Mermel, DO, medical director of infection control for Rhode Island Hospital, looks at the ongoing debate in light of the H1N1 pandemic, what past research tells us about the spread of influenza, and what is missing in the debate. His commentary is currently available in an online first edition.
Case Western Reserve University (CWRU) School of Medicine (SOM) has received a Robert Wood Johnson grant to fund a Public Health Practice Based Research Network called The Ohio Research Association for Public Health Improvement (RAPHI).
A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu.
Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.
SinoFresh Healthcare Products, Inc. announced today the successful results of its initial pilot animal study testing the efficacy of the SinoFresh Nasal Spray product when used on animals infected with the H1N1 virus. The study data suggests that treatment with SinoFresh allowed the infected animals to recover more rapidly from H1N1 infection than did untreated animals. In addition, pre-treatment with SinoFresh Nasal Spray decreased the severity and/or incidence of infection.
Public health officials walking a tightrope between massive demand for vaccines and intense public scrutiny of side effects now have a new standard for evaluating the safety of their vaccination programs.
Researchers at Yale School of Medicine have found that exaggerated responses of the immune system explain why the elderly succumb to viral infections more readily than younger people. Published in the November 19 Cell Host & Microbe, the study bucks the general belief that declining immune responses are to blame for susceptibility to viral infections.
Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission.
Integrated Environmental Technologies, Ltd. announces that Benchmark Performance Group, Inc., its exclusive worldwide distributor serving the oil and gas industry, has completed the expansion of its Excelyte® manufacturing plant at its Midland, Texas facility.
MMR Information Systems, Inc., and Unis-Tonghe Technology (Zhengzhou) Co., Ltd, announced that they will enter into a definitive agreement by the end of this year to form a joint venture to build a customized version of MMR's proprietary personal health record ("PHR") services (www.mymedicalrecords.com) and professional document imaging and management solutions in China.
As flu season got underway this fall, Dr. Catherine Monteleone, an allergist, noticed that her office started to receive an unusually high number of calls from people with egg allergy. They previously had avoided flu vaccines because of their sensitivity to eggs. This year, with all the attention being paid to the novel H1N1 influenza, those patients want to be protected against flu, and they contacted her to find out if they are candidates for inoculation.
Experts believe fear of needles may be preventing people from rolling up their sleeves for the H1N1 vaccination.
mdBriefCase Inc., in collaboration with the Public Health Agency of Canada (PHAC) and the Society of Obstetrics and Gynecology of Canada (SOGC), is pleased to provide a new online education course on the H1N1 virus in pregnant women.
U.S. health officials defended their handling of the country's H1N1 (swine flu) vaccine campaign Tuesday "against criticism that their plan to protect Americans was confusing and over-optimistic," Reuters reports (Fox, 11/17).
CEL-SCI Corporation, a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases and a late-stage oncology company, announced today the start of the Company's first clinical study for hospitalized H1N1 patients at The Johns Hopkins University School of Medicine (Johns Hopkins).
Sinovac Biotech Ltd., a leading developer and provider of vaccines in China, announced today that it received a revised production license from State Food and Drug Administration for Panflu.1, the Company's H1N1 vaccine. The population has been expanded to include people over 60 years old. The shelf life for PANFLU.1 was extended to one year from six months.
Engineer/pilot/attorney Jon Roberts, PhD, has dozens of inventions to his credit. They include technology that thwarts piracy in movie theatres, gadgets that track important items inadvertently left behind, devices to enhance airport security and even an electronic matchmaker that alerts two nearby individuals with similar interests that they have, indeed, found their match.
Rapid influenza diagnostic tests used in doctors' offices, hospitals and medical laboratories to detect H1N1 are virtually useless and could pose a significant danger to public health, according to a Loyola University Medical Center researcher.
IBM (IBM) scientists have created a one-step point-of-care-diagnostic test, based on an innovative silicon chip, that requires less sample volume, is significantly faster, portable, easy to use, and can test for many diseases, including one of world's leading causes of death, cardiovascular disease.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.